Fred Hutchinson Cancer Center
fredhutch.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
538
Active
98
Phase 3
29
Total enrollment
179,320
Pipeline matrix
Showing 40 of 80 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Nicotine Gum | — | — | — | — | — | 1 | |
| Nicotine Patch | — | — | — | — | — | 1 | |
| Nicotine Lozenge | — | — | — | — | — | 1 | |
| Fludarabine | — | — | — | 31 | |||
| Cyclophosphamide | — | — | 90 | ||||
| Mycophenolate Mofetil | — | — | 77 | ||||
| Fludarabine Phosphate | — | — | 80 | ||||
| cyclosporine | — | — | 77 | ||||
| Tacrolimus | — | — | 35 | ||||
| thiotepa | — | — | — | 20 | |||
| Cytarabine | — | — | — | 27 | |||
| methotrexate | — | — | 43 | ||||
| busulfan | — | — | 32 | ||||
| melphalan | — | — | 30 | ||||
| idarubicin | — | — | — | 9 | |||
| Sirolimus | — | — | — | — | 12 | ||
| Treosulfan | — | — | — | — | — | 8 | |
| Recombinant Granulocyte Colony-Stimulating Factor | — | — | — | — | — | 5 | |
| Ruxolitinib | — | — | — | — | — | 4 | |
| Lisocabtagene Maraleucel | — | — | — | — | 3 | ||
| filgrastim | — | — | 29 | ||||
| Bendamustine | — | — | — | — | 4 | ||
| Peripheral Blood Stem Cell | — | — | — | — | — | 2 | |
| Acalabrutinib | — | — | — | — | — | 2 | |
| Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10 | — | — | — | — | — | 2 | |
| JAK Inhibitor | — | — | — | — | — | 2 | |
| Nivolumab | — | — | — | — | 2 | ||
| Mycophenolate Sodium | — | — | — | — | 2 | ||
| Fecal Microbiota Transplantation | — | — | — | — | 2 | ||
| Granulocyte Colony-Stimulating Factor | — | — | — | — | 2 | ||
| prednisone | — | — | — | 8 | |||
| anti-thymocyte globulin | — | — | — | — | 16 | ||
| Rituximab | — | — | — | — | 13 | ||
| Decitabine | — | — | — | — | — | 6 | |
| Vorinostat | — | — | — | — | — | 5 | |
| Pembrolizumab | — | — | — | — | — | 4 | |
| Clofarabine | — | — | — | — | — | 3 | |
| Dilanubicel | — | — | — | — | — | 2 | |
| Lapine T-Lymphocyte Immune Globulin | — | — | — | — | — | 2 | |
| SARS-CoV-2 mRNA Vaccine ARCT-021 | — | — | — | — | — | 1 |
40 more active programs hidden
Next readouts
- 2024-03-29
- 2025-06-09
- 2025-09-04
- 2025-09-29
- 2025-10-27
- 2025-12-30
- 2026-01-22
- 2026-01-23
- 2026-04-03
- 2026-05-31
Top conditions
- Leukemia59
- Recurrent Adult Acute Myeloid Leukemia37
- Recurrent Small Lymphocytic Lymphoma36
- Recurrent Mantle Cell Lymphoma35
- Refractory Chronic Lymphocytic Leukemia35
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities34
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)33
- Lymphoma31
Frequently asked questions about Fred Hutchinson Cancer Center
- How many clinical trials does Fred Hutchinson Cancer Center have on ClinicalTrials.gov?
- Fred Hutchinson Cancer Center is listed as the lead sponsor on 538 clinical trials in ClinicalTrials.gov, 98 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Fred Hutchinson Cancer Center's trials are in Phase 3?
- 29 of Fred Hutchinson Cancer Center's trials are in Phase 3, spread across 80 active drug programs.
- What therapeutic areas does Fred Hutchinson Cancer Center focus on?
- Fred Hutchinson Cancer Center's most-studied conditions on ClinicalTrials.gov are Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Small Lymphocytic Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia.
- When are Fred Hutchinson Cancer Center's next clinical trial readouts?
- Fred Hutchinson Cancer Center has 10 upcoming primary-completion readouts tracked here; the soonest is “A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas”, expected around 2024-03-29.